What drove the EVE.SW stock gain on 16 Feb 2026?

The gain followed stronger intraday buying on **10,527.00** shares and technical strength above the 50-day average; traders also priced in the approaching earnings date of **20 Feb 2026** as a catalyst.

How does Meyka AI rate EVE.SW stock?

Meyka AI rates EVE.SW with **67.90/100** (Grade **B**, **HOLD**). The grade combines benchmark, sector, financial growth, metrics and forecasts and is not investment advice.

What are realistic price targets for EVE.SW stock?

Scenario targets: conservative **CHF1.10**, base **CHF1.45** (year high), and Meyka AI yearly model **CHF2.33**. Use strict risk controls given negative EPS and low liquidity.

When is EvoNext’s next earnings report and why it matters?

EvoNext reports on **20 Feb 2026**; results will clarify cash burn, revenue path and guidance, all likely to drive short-term volatility in EVE.SW stock.

CH Stocks

EvoNext (EVE.SW, SIX) gains 14.12% to CHF0.97 on 16 Feb 2026: next target CHF1.45

ByHuzaifa Zahoor February 17, 2026

The EVE.SW stock jump led Swiss small-caps on 16 Feb 2026 after EvoNext Holdings S.A. closed at CHF0.97, up 14.12% from the prior close, on 10,527.00 shares traded. The move pushed the price above the 50-day average of CHF0.81 and back near the 200-day average of CHF0.97, signalling renewed buying interest in this Biotechnology name on the SIX exchange. As markets closed, traders flagged the upcoming earnings date and a tight cash position as immediate catalysts for follow-through.